FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065236483> ?p ?o ?g. }

• W2065236483 endingPage "35" @default.
• W2065236483 startingPage "26" @default.
• W2065236483 abstract "Urokinase-type plasminogen activator receptor (UPA-R; CD87) is a membrane protein responsible for plasmin expression on cells facilitating cellular extravasations and tissue invasions. We studied the expression of the UPA-R on bone marrow (BM) cells of 93 patients with acute myeloid leukemia at first diagnosis and 8 healthy probands as controls by FACS analysis using phycoerythrin (PE)-conjugated antibodies. A case was defined as UPA-R-positive (UPA-R+) if >20% of the gated cells expressed UPA-R. Whereas none of the 8 healthy BM samples was positive for the UPA-R, 32 (34%) of the 93 AML samples were UPA-R+. Expression of UPA-R was heterogeneous in different FAB types, however, with the highest expression rates in monocytic subtypes (FAB M4/M5): 18%/19%/30% of UPA-R+ cases were found in M1/M2 or M3, and 58%/80% of cases with M4 or M5 were UPA-R+. Proportions of UPA-R+ cells varied between 1% and 98% of the mononuclear cell fractions, with the highest proportions in M4/M5 subtypes (on average 27%/40% UPA-R+ cells) and the lowest expression in AML M2 (11% UPA-R+ cells). The density of expressed UPA-R, estimated as mean channel fluorescence activity, was highest in cases with AML M1 (mFI: 124) followed by M4 and M5 (mFI: 78/77) and lowest in AML M2 (mFI: 43). In sAML, higher proportions of UPA-R+ cases (8 of 18; 44%) compared to pAML (24 of 75; 32%) were found as well as higher proportions of UPA-R+ cells (27% vs. 19%). Separating our patients' cohort in cytogenetic risk groups, we could not detect significant differences in the UPA-R expression profiles. For evaluations of the clinical course of AML, only patients treated by the AML-CG protocol (n = 65) were included. In the group of patients who did not respond to AML-CG therapy, significantly higher proportions of UPA-R+ cells (31% vs. 14%, P = 0.0015, t-test) were found. By evaluating a cut-off value for the percentage of positive cells that allows the most significant separation and differentiation between cases with shorter or longer relapse-free survival times, we could show that patients with >26.5% UPA-R-positive cells were characterized by a significantly higher risk for relapse compared to cases with <26.5% positive cells (P = 0.05). In summary, our data show a high expression of the UPA-R in AML, especially in (myelo)monocytoid subtypes. Cases with higher proportions of UPA-R+ cells were characterized by a significant lower remission rate after AML-CG therapy and a higher risk for relapse. Although prospective trials are still lacking, UPA-R is a prognostically relevant factor independent from the karyotype. UPA-R positivity may identify subtypes of AML associated with a more aggressive clinical course. Thus due to lower remission probabilities in UPA-R+ cases, a more intensive induction therapy regimen could be considered." @default.
• W2065236483 created "2016-06-24" @default.
• W2065236483 creator A5001483935 @default.
• W2065236483 creator A5011108004 @default.
• W2065236483 creator A5036656587 @default.
• W2065236483 creator A5057768807 @default.
• W2065236483 creator A5080313417 @default.
• W2065236483 creator A5086770944 @default.
• W2065236483 date "2005-01-01" @default.
• W2065236483 modified "2023-10-18" @default.
• W2065236483 title "High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis" @default.
• W2065236483 cites W1963911853 @default.
• W2065236483 cites W1979537907 @default.
• W2065236483 cites W1985690665 @default.
• W2065236483 cites W2009740250 @default.
• W2065236483 cites W2032494548 @default.
• W2065236483 cites W2035247318 @default.
• W2065236483 cites W2046078557 @default.
• W2065236483 cites W2053019792 @default.
• W2065236483 cites W2066730945 @default.
• W2065236483 cites W2076426515 @default.
• W2065236483 cites W2162177155 @default.
• W2065236483 cites W2164618443 @default.
• W2065236483 cites W2405442768 @default.
• W2065236483 cites W2407025598 @default.
• W2065236483 cites W2413224675 @default.
• W2065236483 cites W260014646 @default.
• W2065236483 doi "https://doi.org/10.1002/ajh.20337" @default.
• W2065236483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15849776" @default.
• W2065236483 hasPublicationYear "2005" @default.
• W2065236483 type Work @default.
• W2065236483 sameAs 2065236483 @default.
• W2065236483 citedByCount "33" @default.
• W2065236483 countsByYear W20652364832012 @default.
• W2065236483 countsByYear W20652364832013 @default.
• W2065236483 countsByYear W20652364832014 @default.
• W2065236483 countsByYear W20652364832015 @default.
• W2065236483 countsByYear W20652364832016 @default.
• W2065236483 countsByYear W20652364832017 @default.
• W2065236483 countsByYear W20652364832018 @default.
• W2065236483 countsByYear W20652364832020 @default.
• W2065236483 countsByYear W20652364832021 @default.
• W2065236483 countsByYear W20652364832022 @default.
• W2065236483 countsByYear W20652364832023 @default.
• W2065236483 crossrefType "journal-article" @default.
• W2065236483 hasAuthorship W2065236483A5001483935 @default.
• W2065236483 hasAuthorship W2065236483A5011108004 @default.
• W2065236483 hasAuthorship W2065236483A5036656587 @default.
• W2065236483 hasAuthorship W2065236483A5057768807 @default.
• W2065236483 hasAuthorship W2065236483A5080313417 @default.
• W2065236483 hasAuthorship W2065236483A5086770944 @default.
• W2065236483 hasBestOaLocation W20652364831 @default.
• W2065236483 hasConcept C126322002 @default.
• W2065236483 hasConcept C142724271 @default.
• W2065236483 hasConcept C153911025 @default.
• W2065236483 hasConcept C181199279 @default.
• W2065236483 hasConcept C203014093 @default.
• W2065236483 hasConcept C2778461978 @default.
• W2065236483 hasConcept C2778729363 @default.
• W2065236483 hasConcept C2779282312 @default.
• W2065236483 hasConcept C2779679481 @default.
• W2065236483 hasConcept C2781071845 @default.
• W2065236483 hasConcept C502942594 @default.
• W2065236483 hasConcept C55493867 @default.
• W2065236483 hasConcept C56219504 @default.
• W2065236483 hasConcept C71924100 @default.
• W2065236483 hasConcept C86803240 @default.
• W2065236483 hasConceptScore W2065236483C126322002 @default.
• W2065236483 hasConceptScore W2065236483C142724271 @default.
• W2065236483 hasConceptScore W2065236483C153911025 @default.
• W2065236483 hasConceptScore W2065236483C181199279 @default.
• W2065236483 hasConceptScore W2065236483C203014093 @default.
• W2065236483 hasConceptScore W2065236483C2778461978 @default.
• W2065236483 hasConceptScore W2065236483C2778729363 @default.
• W2065236483 hasConceptScore W2065236483C2779282312 @default.
• W2065236483 hasConceptScore W2065236483C2779679481 @default.
• W2065236483 hasConceptScore W2065236483C2781071845 @default.
• W2065236483 hasConceptScore W2065236483C502942594 @default.
• W2065236483 hasConceptScore W2065236483C55493867 @default.
• W2065236483 hasConceptScore W2065236483C56219504 @default.
• W2065236483 hasConceptScore W2065236483C71924100 @default.
• W2065236483 hasConceptScore W2065236483C86803240 @default.
• W2065236483 hasIssue "1" @default.
• W2065236483 hasLocation W20652364831 @default.
• W2065236483 hasLocation W20652364832 @default.
• W2065236483 hasOpenAccess W2065236483 @default.
• W2065236483 hasPrimaryLocation W20652364831 @default.
• W2065236483 hasRelatedWork W1478983315 @default.
• W2065236483 hasRelatedWork W1523192999 @default.
• W2065236483 hasRelatedWork W1607740737 @default.
• W2065236483 hasRelatedWork W1984762222 @default.
• W2065236483 hasRelatedWork W2039856336 @default.
• W2065236483 hasRelatedWork W2078706638 @default.
• W2065236483 hasRelatedWork W2080202380 @default.
• W2065236483 hasRelatedWork W2085429393 @default.
• W2065236483 hasRelatedWork W2126524937 @default.
• W2065236483 hasRelatedWork W3094919433 @default.
• W2065236483 hasVolume "79" @default.

• next